BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat. 1998;5:241-248. [PMID: 9751010 DOI: 10.1046/j.1365-2893.1998.00109.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev 2000;13:385-407. [PMID: 10885983 DOI: 10.1128/CMR.13.3.385] [Cited by in Crossref: 86] [Cited by in F6Publishing: 73] [Article Influence: 4.1] [Reference Citation Analysis]
2 Cameron-Wilson CL, Muir P, Ballard AL, Corden S, Boxall EH, Sablon E, Stuyver L. Evaluation of a line probe assay for identification of hepatitis B virus precore variants in serum from chronic hepatitis B carriers. J Virol Methods. 2003;114:97-103. [PMID: 14599684 DOI: 10.1016/j.jviromet.2003.09.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
3 Alexopoulou A, Karayiannis P. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. World J Gastroenterol. 2014;20:7644-7652. [PMID: 24976702 DOI: 10.3748/wjg.v20.i24.7644] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
4 Manesis EK, Papatheodoridis GV, Hadziyannis SJ. A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2006;23:99-106. [PMID: 16393286 DOI: 10.1111/j.1365-2036.2006.02731.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
5 Huang YH, Wu JC, Chang TT, Sheen IJ, Huo TI, Lee PC, Su CW, Lee SD. Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients. J Viral Hepat. 2006;13:336-342. [PMID: 16637865 DOI: 10.1111/j.1365-2893.2005.00688.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
6 Elefsiniotis IS, Ketikoglou I, Kafiri G, Pantazis KD, Moulakakis A, Mavrogiannis C. Plasma pituitary adenylate cyclase activating polypeptide (PACAP) levels in chronic hepatitis B patients under lamivudine treatment: . European Journal of Gastroenterology & Hepatology 2003;15:1209-16. [DOI: 10.1097/00042737-200311000-00010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
7 Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat. 2002;9:52-61. [PMID: 11851903 DOI: 10.1046/j.1365-2893.2002.00304.x] [Cited by in Crossref: 245] [Cited by in F6Publishing: 213] [Article Influence: 12.9] [Reference Citation Analysis]
8 Chan HL, Leung NW, Hussain M, Wong ML, Lok AS. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology. 2000;31:763-768. [PMID: 10706570 DOI: 10.1002/hep.510310330] [Cited by in Crossref: 132] [Cited by in F6Publishing: 129] [Article Influence: 6.3] [Reference Citation Analysis]
9 Chiou HC, Lucas MA, Coffin CC, Banaszczyk MG, Ill CR, Lollo CP. Gene therapy strategies for the treatment of chronic viral hepatitis. Expert Opin Biol Ther. 2001;1:629-639. [PMID: 11727499 DOI: 10.1517/14712598.1.4.629] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
10 Makondo E, Bell TG, Kramvis A. Genotyping and molecular characterization of hepatitis B virus from human immunodeficiency virus-infected individuals in southern Africa. PLoS One. 2012;7:e46345. [PMID: 23029487 DOI: 10.1371/journal.pone.0046345] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
11 Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology. 2000;32:1163-1169. [PMID: 11050070 DOI: 10.1053/jhep.2000.19618] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.0] [Reference Citation Analysis]
12 Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. [PMID: 29877316 DOI: 10.1038/nrdp.2018.35] [Cited by in Crossref: 172] [Cited by in F6Publishing: 139] [Article Influence: 57.3] [Reference Citation Analysis]
13 Belyhun Y, Liebert UG, Maier M. Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia. PLoS One 2018;13:e0191970. [PMID: 29408943 DOI: 10.1371/journal.pone.0191970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Khan M, Dong JJ, Acharya SK, Dhagwahdorj Y, Abbas Z, Jafri Sm W, Mulyono DH, Tozun N, Sarin SK. Hepatology issues in Asia: Perspectives from regional leaders. J Gastroenterol Hepatol 2004;19:S419-30. [DOI: 10.1111/j.1440-1746.2004.03728.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
15 Ledesma MM, Galdame O, Bouzas B, Tadey L, Livellara B, Giuliano S, Viaut M, Paz S, Fainboim H, Gadano A, Campos R, Flichman D. Characterization of the basal core promoter and precore regions in anti-HBe-positive inactive carriers of hepatitis B virus. Int J Infect Dis 2011;15:e314-20. [PMID: 21367634 DOI: 10.1016/j.ijid.2010.12.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
16 Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs. 1999;58:101-141. [PMID: 10439933 DOI: 10.2165/00003495-199958010-00015] [Cited by in Crossref: 96] [Cited by in F6Publishing: 69] [Article Influence: 4.4] [Reference Citation Analysis]
17 Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat. 2004;11:432-438. [PMID: 15357648 DOI: 10.1111/j.1365-2893.2004.00556.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 5.9] [Reference Citation Analysis]
18 Liatsos C, Mehta AB, Potter M, Burroughs AK. The hepatologist in the haematologists‘ camp. Br J Haematol. 2001;113:567-578. [PMID: 11380440 DOI: 10.1046/j.1365-2141.2001.02628.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
19 Lee SA, Cho YK, Lee KH, Hwang ES, Kook YH, Kim BJ. Gender disparity in distribution of the major hydrophilic region variants of hepatitis B virus genotype C according to hepatitis B e antigen serostatus. J Med Virol 2011;83:405-11. [PMID: 21264860 DOI: 10.1002/jmv.21988] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
20 El-Zayadi AR, Badran HM, Saied A, Shawky S, Attia Mel-D, Zalata K. Evaluation of liver biopsy in Egyptian HBeAg-negative chronic hepatitis B patients at initial presentation: implications for therapy. Am J Gastroenterol. 2009;104:906-911. [PMID: 19293791 DOI: 10.1038/ajg.2009.30] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
21 Corden S, Ballard AL, Ijaz S, Barbara JA, Gilbert N, Gilson RJ, Boxall EH, Tedder RS. HBV DNA levels and transmission of hepatitis B by health care workers. J Clin Virol. 2003;27:52-58. [PMID: 12727529 DOI: 10.1016/s1386-6532(02)00127-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
22 Jardi R, Rodriguez F, Buti M, Costa X, Valdes A, Allende H, Schaper M, Galimany R, Esteban R, Guardia J. Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. J Hepatol. 2004;40:507-514. [PMID: 15123367 DOI: 10.1016/j.jhep.2003.11.015] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
23 Wright TL. Introduction to chronic hepatitis B infection. Am J Gastroenterol. 2006;101 Suppl 1:S1-S6. [PMID: 16448446 DOI: 10.1111/j.1572-0241.2006.00469.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 97] [Article Influence: 6.6] [Reference Citation Analysis]
24 Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat. 2001;8:311-321. [PMID: 11555188 DOI: 10.1046/j.1365-2893.2001.00303.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 3.6] [Reference Citation Analysis]
25 Saha D, Pal A, Biswas A, Panigrahi R, Sarkar N, Das D, Sarkar J, Guha SK, Saha B, Chakrabarti S, Chakravarty R. Molecular characterization of HBV strains circulating among the treatment-naive HIV/HBV co-infected patients of eastern India. PLoS One. 2014;9:e90432. [PMID: 24587360 DOI: 10.1371/journal.pone.0090432] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
26 Akinbami AA, Oshinaike OO, Dosunmu OA, Adeyemo TA, Adediran A, Akanmu S, Wright KO, Ilori S, Aile K. Seroprevalence of hepatitis B e antigen (HBe antigen) and B core antibodies (IgG anti-HBcore and IgM anti-HBcore) among hepatitis B surface antigen positive blood donors at a Tertiary Centre in Nigeria. BMC Res Notes 2012;5:167. [PMID: 22455501 DOI: 10.1186/1756-0500-5-167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
27 Ngui SL, Hallet R, Teo CG. Natural and iatrogenic variation in hepatitis B virus. Rev Med Virol 1999;9:183-209. [PMID: 10479779 DOI: 10.1002/(sici)1099-1654(199907/09)9:3<183::aid-rmv248>3.0.co;2-p] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
28 Ingman M, Lindqvist B, Kidd-ljunggren K. Novel mutation in Hepatitis B virus preventing HBeAg production and resembling primate strains. Journal of General Virology 2006;87:307-10. [DOI: 10.1099/vir.0.81562-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Lin C, Zou H, Wang S. Hepatitis B e Antigen Seroconversion Is Related with the Function of Dendritic Cells in Chronic Hepatitis B Virus Infection. Gastroenterol Res Pract. 2014;2014:413952. [PMID: 25574162 DOI: 10.1155/2014/413952] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
30 Fung SK, Wong FS, Wong DK, Hussain MT, Lok AS. Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. Liver Int. 2006;26:796-804. [PMID: 16911461 DOI: 10.1111/j.1478-3231.2006.01297.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
31 Galli C, Orlandini E, Penzo L, Badiale R, Caltran G, Valverde S, Gessoni G. What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology? J Med Virol 2008;80:974-9. [PMID: 18428144 DOI: 10.1002/jmv.21179] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
32 Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, Schröter M, Laufs R, Feucht HH. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology. 2004;39:42-50. [PMID: 14752821 DOI: 10.1002/hep.20016] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 4.6] [Reference Citation Analysis]
33 Ribeiro RM, Germanidis G, Powers KA, Pellegrin B, Nikolaidis P, Perelson AS, Pawlotsky JM. Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. J Infect Dis. 2010;202:1309-1318. [PMID: 20874517 DOI: 10.1086/656528] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
34 Elefsiniotis IS, Mpotsi C, Paparizos V, Pantazis KD. Long-term follow-up of HIV/HBV coinfected patients from a Greek center. J Clin Virol 2004;30:280-1. [PMID: 15135750 DOI: 10.1016/j.jcv.2003.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Cheng H, Zhang HZ, Shen WA, Liu YF, Ma FC. Expression of RNase H of human hepatitis B virus polymerase in Escherichia coli. World J Gastroenterol 2003;9:513-5. [PMID: 12632508 DOI: 10.3748/wjg.v9.i3.513] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Laras A, Koskinas J, Hadziyannis SJ. In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter. Virology. 2002;295:86-96. [PMID: 12033768 DOI: 10.1006/viro.2001.1352] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
37 Fouad R, Musa S, Sabry D, Salama A, Alem SA, Atef M, Zayed N. Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients. Afr Health Sci 2020;20:649-55. [PMID: 33163026 DOI: 10.4314/ahs.v20i2.13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Villeneuve JP. The natural history of chronic hepatitis B virus infection. J Clin Virol. 2005;34 Suppl 1:S139-S142. [PMID: 16461215 DOI: 10.1016/s1386-6532(05)80024-1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
39 Manesis EK. HBeAg-negative chronic hepatitis B: From obscurity to prominence. Journal of Hepatology 2006;45:343-6. [DOI: 10.1016/j.jhep.2006.07.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
40 Flichman D, Galdame O, Livellara B, Viaut M, Gadano A, Campos R. Full-length genome characterization of hepatitis B virus genotype H strain isolated from serum samples collected from two chronically infected patients in Argentina. J Clin Microbiol. 2009;47:4191-4193. [PMID: 19794035 DOI: 10.1128/jcm.01337-09] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
41 Chachá SGF, Gomes-Gouvêa MS, Malta FM, Ferreira SDC, Villanova MG, Souza FF, Teixeira AC, Passos ADDC, Pinho JRR, Martinelli ALC. Basal core promoter and precore mutations among hepatitis B virus circulating in Brazil and its association with severe forms of hepatic diseases. Mem Inst Oswaldo Cruz 2017;112:626-31. [PMID: 28902288 DOI: 10.1590/0074-02760160540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
42 Sarin SK, Satapathy SK, Chauhan R. Hepatitis B e-antigen negative chronic hepatitis B. J Gastroenterol Hepatol 2002;17 Suppl 3:S311-21. [PMID: 12472956 DOI: 10.1046/j.1440-1746.17.s3.20.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
43 Sun X, Rokuhara A, Tanaka E, Gad A, Mutou H, Matsumoto A, Yoshizawa K, Kiyosawa K. Nucleotide mutations associated with hepatitis B e antigen negativity. J Med Virol 2005;76:170-5. [DOI: 10.1002/jmv.20340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
44 François G, Kew M, Van Damme P, Mphahlele M, Meheus A. Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications? Vaccine 2001;19:3799-815. [DOI: 10.1016/s0264-410x(01)00108-6] [Cited by in Crossref: 69] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
45 Chen YM, Wu SH, Qiu CN, Yu DJ, Wang XJ. Hepatitis B virus subgenotype C2- and B2-associated mutation patterns may be responsible for liver cirrhosis and hepatocellular carcinoma, respectively. Braz J Med Biol Res 2013;46:614-22. [PMID: 23903686 DOI: 10.1590/1414-431X20133032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
46 Samal J, Kandpal M, Vivekanandan P. HBeAg-induced miR-106b promotes cell growth by targeting the retinoblastoma gene. Sci Rep 2017;7:14371. [PMID: 29085029 DOI: 10.1038/s41598-017-14652-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
47 Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev. 2000;13:385-407. [PMID: 10885983 DOI: 10.1128/cmr.13.3.385-407.2000] [Cited by in Crossref: 175] [Article Influence: 8.3] [Reference Citation Analysis]
48 Yoo BC, Park J, Kim HJ, Lee DH, Cha YJ, Park SM. Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. Journal of Hepatology 2003;38:98-103. [DOI: 10.1016/s0168-8278(02)00349-5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
49 Samal J, Kandpal M, Vivekanandan P. Hepatitis B “e” antigen-mediated inhibition of HBV replication fitness and transcription efficiency in vitro. Virology 2015;484:234-40. [DOI: 10.1016/j.virol.2015.06.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
50 Andreone P, Biselli M, Gramenzi A, Cursaro C, Morelli MC, Sama C, Lorenzini S, Spinucci G, Porzio F, Felline F. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation. 2002;74:1119-1124. [PMID: 12438957 DOI: 10.1097/00007890-200210270-00011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
51 Minuk GY, Orr PS, Brown R, Macdonald S, Chaudhary RK, Temple P. Pre-core mutant infections in the Canadian Inuit. Journal of Hepatology 2000;33:781-4. [DOI: 10.1016/s0168-8278(00)80310-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
52 Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2000;32:847-851. [PMID: 11003633 DOI: 10.1053/jhep.2000.17915] [Cited by in Crossref: 252] [Cited by in F6Publishing: 224] [Article Influence: 12.0] [Reference Citation Analysis]
53 Gaia S, Marzano A, Smedile A, Barbon V, Abate ML, Olivero A, Lagget M, Paganin S, Fadda M, Niro G. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2004;20:281-287. [PMID: 15274664 DOI: 10.1111/j.1365-2036.2004.02073.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
54 Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999;29:889-896. [PMID: 10051494 DOI: 10.1002/hep.510290321] [Cited by in Crossref: 346] [Cited by in F6Publishing: 300] [Article Influence: 15.7] [Reference Citation Analysis]
55 Yim HJ. [Hepatitis B virus genetic diversity and mutant]. Korean J Hepatol. 2008;14:446-464. [PMID: 19119240 DOI: 10.3350/kjhep.2008.14.4.446] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
56 Colombatto P, Barbera C, Bortolotti F, Maina AM, Moriconi F, Cavallone D, Calvo P, Oliveri F, Bonino F, Brunetto MR. HBV pre-core mutant in genotype-D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood. J Med Virol 2018;90:1232-9. [PMID: 29488227 DOI: 10.1002/jmv.25068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
57 Kaymakoglu S, Danalioglu A, Demir K, Karaca C, Akyuz F, Onel D, Badur S, Cevikbas U, Besisik F, Cakaloglu Y, Okten A. Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B. Dig Dis Sci 2007;52:727-31. [PMID: 17237999 DOI: 10.1007/s10620-006-9445-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
58 Hatzakis A, Magiorkinis E, Haida C. HBV virological assessment. J Hepatol. 2006;44:S71-S76. [PMID: 16343681 DOI: 10.1016/j.jhep.2005.11.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
59 Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol. 2011;55:61-68. [PMID: 21145875 DOI: 10.1016/j.jhep.2010.10.027] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
60 Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B. Journal of Hepatology 2001;34:306-13. [DOI: 10.1016/s0168-8278(00)00094-5] [Cited by in Crossref: 209] [Cited by in F6Publishing: 46] [Article Influence: 10.5] [Reference Citation Analysis]
61 Pollicino T, Caminiti G. HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses 2021;13:368. [PMID: 33652619 DOI: 10.3390/v13030368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Regev A, Schiff ER. Viral hepatitis A, B, and C. Clin Liver Dis 2000;4:47-71, vi. [PMID: 11232191 DOI: 10.1016/s1089-3261(05)70096-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]